Acamprol Tablet (Acamprosate 333)

Description

Acamprol Tablet (Acamprosate 333) — Complete Clinical and Patient Information Guide

Product Overview

Acamprol Tablet (Acamprosate 333) contains Acamprosate Calcium 333mg as its active pharmaceutical ingredient, belonging to the NMDA glutamate receptor modulator + GABA-A receptor potentiator — anti-craving agent for alcohol dependence. It is clinically indicated for maintenance of alcohol abstinence in patients with alcohol dependence as part of a comprehensive treatment programme including counselling — most effective when started after achieving initial abstinence. This comprehensive guide has been developed in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines to provide accurate, evidence-based information for patients and healthcare professionals.

Acamprol 333mg provides acamprosate at the standard tablet dose. The trademark Acamprol brand is one of the most widely prescribed acamprosate formulations in India, supporting abstinence maintenance after achieving sobriety in alcohol-dependent patients.

Understanding Acamprol 333mg and Its Active Ingredient

Acamprosate Calcium 333mg is the pharmacologically active compound in Acamprol 333mg. The drug class to which it belongs — NMDA glutamate receptor modulator + GABA-A receptor potentiator — anti-craving agent for alcohol dependence — has a well-established clinical evidence base developed across decades of research, regulatory review, and real-world clinical use. Understanding the mechanism of action, appropriate therapeutic use, necessary monitoring, and safety considerations of this medication is essential for achieving optimal clinical outcomes while protecting patient safety.

This product should only be used under appropriate medical supervision. For medications classified as YMYL (conditions where improper use carries significant health risk), professional medical guidance before initiating, modifying, or stopping therapy is not optional — it is a fundamental patient safety requirement. Patients are encouraged to maintain open, honest communication with their prescribing physician and pharmacist about all aspects of their treatment.

Mechanism of Action

Acamprosate calcium (calcium bis-acetylhomotaurine) is a synthetic analogue of the inhibitory neurotransmitter GABA that acts primarily as a modulator of the N-methyl-D-aspartate (NMDA) receptor-gated glutamate system, with additional activity at GABA-A receptors. Chronic alcohol consumption produces a neuroadaptive state of glutamatergic hyperactivity and GABAergic hypofunction: the brain upregulates excitatory NMDA receptors and downregulates inhibitory GABA receptors to compensate for alcohol’s acute CNS depressant effects. When alcohol is discontinued, this neuroadaptive state is unmasked — producing the characteristic hyperexcitable alcohol withdrawal syndrome (anxiety, tremor, seizures, autonomic instability). More subtly, the persisting glutamate/GABA imbalance in abstinent alcoholics contributes to ongoing dysphoria, anxiety, sleep disturbance, and protracted craving — the neurological substrate of post-acute withdrawal syndrome (PAWS) that drives relapse in the weeks and months after achieving sobriety. Acamprosate normalises this dysregulated neurotransmitter balance: it reduces NMDA receptor-mediated glutamate excitotoxicity and potentiates GABA-A receptor inhibitory activity, restoring the normal excitatory/inhibitory balance in limbic and cortical circuits. The result is reduction in the neurological discomfort and craving associated with early and sustained abstinence, making it significantly easier for patients to maintain sobriety.

Understanding how this medication works at the molecular and cellular level helps explain the clinical requirements for optimal use: why specific timing, administration conditions, monitoring tests, contraindications, and drug interactions exist. Healthcare providers apply this mechanistic understanding to individualise therapy, anticipate drug interactions, counsel patients on what to expect, and monitor for treatment response and toxicity.

Clinical Indications

Acamprol Tablet (Acamprosate 333) is clinically indicated for:

• Primary indication: maintenance of alcohol abstinence in patients with alcohol dependence as part of a comprehensive treatment programme including counselling — most effective when started after achieving initial abstinence
• Confirmed diagnosis required: A qualified healthcare professional must confirm the diagnosis and determine appropriateness of this specific medication for the individual patient. Self-diagnosis and self-treatment with prescription medications carries significant and potentially serious health risks.
• Treatment goals and monitoring: The prescribing physician establishes clear therapeutic objectives and a monitoring plan appropriate to the specific indication and the patient’s individual risk profile.

Dosage and Administration

Two tablets (666mg) three times daily (with meals) for a total daily dose of 1998mg. Must be started only after the patient has achieved initial alcohol abstinence. Continue for 12 months or longer as prescribed. If a relapse occurs, do not stop acamprosate — resume treatment and engage counselling support. Unlike disulfiram, acamprosate does not produce an adverse interaction with alcohol, and treatment should be maintained even if the patient relapses to drinking.

Adherence to the prescribed dosing regimen is critical for therapeutic success and patient safety. Patients uncertain about their dosing schedule should contact their prescribing physician or pharmacist before making any changes. Never alter doses or stop therapy without medical advice, particularly for medications (such as systemic retinoids, alcohol dependence therapies, and corticosteroids) where abrupt changes can have significant consequences.

Who Should Use Acamprol 333mg

Acamprol 333mg is indicated for adult patients (and where specified, adolescent patients) who have been diagnosed by a qualified healthcare professional with the conditions listed in the indications section, and for whom this medication has been determined appropriate following assessment of individual benefits and risks. Patients should have no absolute contraindications and should be able to comply with any required monitoring or safety programme requirements.

Contraindications — Who Should Not Use Acamprol 333mg

Severe renal impairment (eGFR <30ml/min — acamprosate is renally excreted and dose reduction is required for moderate impairment, contraindicated in severe impairment). Hypersensitivity to acamprosate or any excipient. Not for use in patients with significant hepatic impairment. Not started in patients who are currently drinking significant amounts of alcohol (initiate after achieving abstinence).

Before starting Acamprol 333mg, patients must provide their prescribing physician with a complete medical history, including all current medications (prescription and over-the-counter), known allergies, and relevant personal and family medical history. Conditions that appear unrelated to the treatment indication may significantly affect prescribing decisions for drugs with complex safety profiles.

Drug Interactions

Acamprosate has minimal pharmacokinetic drug interactions as it is not significantly protein-bound and is not metabolised by CYP450 enzymes — one of its practical clinical advantages. Naltrexone: can be combined safely with acamprosate — the COMBINE study demonstrated that the combination is clinically feasible (though not superior to either agent alone in all populations). Alcohol: acamprosate does not produce an adverse reaction with alcohol, unlike disulfiram.

Drug interactions can be clinically significant and potentially dangerous. A complete medication review by a qualified pharmacist or physician is essential before starting Acamprol 333mg. Many interactions can be effectively managed through dose adjustment, temporal separation of doses, or alternative drug selection — but only when proactively identified. Patients should never add new medications (including herbal supplements and over-the-counter products) without checking for interactions with Acamprol 333mg.

Adverse Effects and Side Effects

Common: diarrhoea (most frequent GI side effect — dose-limiting in some patients; may improve with dose titration or temporary reduction), nausea, and abdominal pain. Skin reactions — pruritus and rash. Generally very well tolerated with a safety profile similar to placebo in clinical trials except for GI effects. No hepatotoxic or central sedating effects — a clinical advantage over other alcohol dependence medications.

Side effects vary in frequency, severity, and clinical significance. Patients should be educated before starting treatment about which side effects to expect and manage (expected retinisation with retinoids, mucocutaneous dryness with isotretinoin) versus which require prompt medical attention (signs of disulfiram-ethanol reaction, symptoms of pseudotumour cerebri, signs of hepatotoxicity). A proactive approach to side-effect education significantly improves treatment adherence and patient safety.

Special Population Considerations

Alcohol dependence — integrated treatment: Pharmacotherapy alone is rarely sufficient for sustained recovery from alcohol dependence. All pharmacological treatments are most effective when integrated with psychosocial interventions — cognitive behavioural therapy (CBT), motivational enhancement therapy (MET), 12-step facilitation, SMART Recovery, or other structured support programmes. The combination of medication and psychological support produces significantly better outcomes than either alone.

Medical supervision: Management of alcohol dependence and withdrawal is a medically complex area requiring specialist input. Alcohol withdrawal can be life-threatening (delirium tremens, Wernicke’s encephalopathy, seizures) and requires supervised management. Never attempt alcohol withdrawal without medical assessment and supervision, particularly after heavy or prolonged alcohol use.

Liver monitoring: Most pharmacotherapies for alcohol dependence require baseline and periodic liver function tests, as many patients with alcohol use disorder have underlying hepatic damage that may influence drug metabolism and toxicity. Disulfiram and naltrexone particularly require regular liver function monitoring.

Concurrent mental health: Depression, anxiety, PTSD, and other mental health conditions co-occur with alcohol dependence in the majority of patients. Comprehensive management should screen for and address comorbid psychiatric conditions, which if untreated significantly increase relapse risk.

Starting timing: Acamprosate should ideally be started within a few days of achieving alcohol abstinence — before the neurological craving that drives early relapse becomes established. It is most effective when started promptly after detoxification and continued for at least 12 months.

Complementary to naltrexone: Acamprosate and naltrexone have different mechanisms and can be combined in patients who are unable to maintain abstinence on monotherapy. They address different aspects of alcohol dependence neurobiology — acamprosate addresses the glutamate/GABA imbalance of post-acute withdrawal, while naltrexone addresses opioid-mediated alcohol craving.

Storage and Handling

Store Acamprol 333mg at room temperature (15–25°C) in a dry location away from direct sunlight, heat sources, and moisture. Keep in the original manufacturer’s packaging until required. Secure out of reach of children and pets. Do not use beyond the printed expiry date. Dispose of unused or expired medication through authorised pharmaceutical take-back services — do not flush down drains or discard in household waste, as pharmaceutical waste poses environmental hazards.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children and pets. Do not use beyond the printed expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember, unless it is nearly time for the next scheduled dose. Never double-dose. Consult your prescriber if uncertain about how to manage a missed dose in your specific regimen.

Q: Should I stop acamprosate if I have a relapse?
A: No — do not stop acamprosate if you have a relapse (drink alcohol). Resume abstinence efforts with counselling support and continue taking acamprosate. Acamprosate does not produce a dangerous reaction with alcohol, and the clinical trials supporting its use included patients who relapsed and resumed treatment. A single relapse is not a treatment failure — it is part of the recovery process for many patients.

Q: How is acamprosate different from naltrexone?
A: Acamprosate normalises the glutamate/GABA neurochemical imbalance that causes post-acute withdrawal symptoms (anxiety, insomnia, dysphoria, craving) in abstinent alcoholics — addressing the neurological discomfort of sobriety that drives relapse. Naltrexone blocks the opioid-mediated reward of alcohol — addressing the positive reinforcement that makes drinking attractive. They target different mechanisms and can be used together.

Clinical Evidence and Quality Standards

The active ingredient in Acamprol 333mg has been evaluated in randomised controlled trials, meta-analyses, and extensive post-marketing surveillance studies supporting its use in the approved indications. Major international clinical guidelines — including those from the British Association of Dermatologists, American Academy of Dermatology, European Dermatology Forum, National Institute for Health and Care Excellence (NICE), and relevant specialty societies — incorporate this drug class in their evidence-based treatment algorithms, reflecting a high level of clinical confidence in its efficacy and safety profile when used appropriately.

Acamprol 333mg is manufactured in compliance with Good Manufacturing Practice (GMP) standards required by national and international pharmaceutical regulatory authorities. GMP certification ensures consistent product quality, identity, strength, purity, and safety across all manufactured batches. Patients should only obtain prescription medications from licensed pharmacies with a valid prescription to ensure they receive authentic, properly stored, regulatory-compliant products.

Important Medical Disclaimer

This product information page is provided for general educational purposes only, developed in accordance with YMYL (Your Money Your Life) content standards. The information presented draws on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines. It is not a substitute for professional medical advice, diagnosis, or treatment from a qualified physician, dermatologist, addiction medicine specialist, or pharmacist. Drug therapy decisions must be individualised based on the complete clinical picture, comorbidities, and concurrent medications of each patient. Self-diagnosis and self-treatment of conditions managed by prescription medications can be dangerous and may lead to delayed diagnosis of serious underlying conditions, inappropriate drug use, or preventable adverse events. Always consult a qualified healthcare professional before starting, changing, or stopping this or any medication.